SUPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
SUPERNUS PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$39.84+1.96 (+5.17%)
Close on Oct 19, 2026
- Market cap
- $2.31B
- P/E (TTM)
- –
- Dividend yield
- –
SUPERNUS PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $626.54M | $637.70M | $573.93M | $649.43M | $567.50M | $509.35M | $383.40M | $399.87M | $294.10M | $210.08M | 87.1% | -1.8% |
| Qelbree | $304.65M | $241.27M | $140.19M | $61.32M | $9.88M | $0 | $0 | – | – | – | 42.4% | +26.3% |
| GOCOVRI | $146.82M | $130.82M | $119.64M | $104.42M | $9.78M | $0 | $0 | – | – | – | 20.4% | +12.2% |
| Collaboration revenue (ZURZUVAE) | $53.00M | $0 | $0 | – | – | – | – | – | – | – | 7.4% | – |
| APOKYN | $47.77M | $73.93M | $75.08M | $75.31M | $99.23M | $74.30M | $0 | $0 | – | – | 6.6% | -35.4% |
| Trokendi XR | $42.42M | $63.20M | $94.34M | $261.22M | $304.82M | $319.64M | $295.21M | $315.30M | $226.52M | – | 5.9% | -32.9% |
| Oxtellar XR | $40.70M | $99.46M | $113.40M | $115.35M | $110.71M | $98.73M | $88.19M | $84.58M | $67.58M | $51.69M | 5.7% | -59.1% |
| Royalty, licensing, and other revenues | $39.42M | $24.12M | $33.59M | $17.81M | – | – | – | – | – | – | 5.5% | +63.4% |
| Other | $26.91M | $29.01M | $31.28M | $31.82M | $33.09M | $16.69M | – | – | – | – | 3.7% | -7.2% |
| ONAPGO | $17.25M | $0 | $0 | – | – | – | – | – | – | – | 2.4% | – |
| License | – | – | – | – | – | $0 | $0 | $750.00K | $1.77M | $239.00K | – | – |
| Royalty and licensing revenues | – | – | $33.59M | $17.81M | $12.27M | $11.05M | $9.36M | $8.28M | $6.37M | $4.69M | – | – |
| Trokendi XR | – | – | – | – | – | – | – | $315.30M | $226.52M | $158.38M | – | – |
| Milestone revenue | – | – | – | – | – | – | – | $750.00K | $1.50M | – | – | – |
| XADAGO | – | – | – | – | $13.39M | $6.94M | $0 | $0 | – | – | – | – |
| MYOBLOC | – | – | – | – | $19.51M | $9.75M | $0 | $0 | – | – | – | – |
| Osmolex ER | – | – | – | – | $188.00K | $0 | $0 | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Supernus Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.